These results suggest that while cabozantinib monotherapy possesses limited effectiveness in c-Myc-driven orthotopic liver cancer models, its combination with chloroquine or XRK3F2 markedly amplifies its anti-cancer properties. This evidence concerns the gene MYC and cancer.